Fidelity Advisor Small Cap Growth Fund: Class I (FCIGX)
This investment fund primarily seeks growth opportunities within the equity market. It commits at least 80% of its assets to companies with smaller market capitalizations. Fidelity Management & Research Company (FMR) identifies and selects businesses believed to possess above-average growth potential, often categorized as "growth" stocks. The fund's holdings include both domestic and international issuers. Investment decisions are underpinned by a comprehensive fundamental analysis, examining factors such as a company's financial health, its standing within its industry, and the prevailing market and economic conditions.
FCIGX Mutual Fund Chart & Stats
- Previous Close
- $32.81
- Sub-Category
- Small Cap
- Total Liabilities
- $414.28M
- Last Dividend Ex-Date
- Sep 11, 2026
- Expense Ratio
- 0.90%
- Holding Count
- 305
- Brand
- Fidelity Securities Fund
- Dividend Yield
- (23.98%)
- Category
- Equity
- Total Assets
- 9.21B
- Shares Outstanding
- N/A
- 52-Week Range
- $31.97 - $45.28
FCIGX Mutual Fund News
Spyre Therapeutics Faces Ongoing Dilution Risk and Strategic Constraints From Heavy Reliance on External Financing
Spyre Therapeutics, Inc (SYRE) has disclosed a new risk, in the Share Price & Shareholder Rights category. Spyre Therapeutics, Inc is expected to rely heavily on external financing until its
FCIGX Mutual Fund Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| USD_CASHFidelity Revere Street Trust | 4.31% |
| USD_CASHFidelity Revere Street Trust | 1.70% |
| BTSGBrightSpring Health Services, Inc. | 1.36% |
| ENVAEnova International Inc. | 1.15% |
| COGTCogent Biosciences, Inc. | 1.11% |
| IDCCInterdigital | 1.03% |
| INTAIntapp, Inc. | 1.01% |
| RSIRush Street Interactive, Inc. | 0.87% |
| SYRESpyre Therapeutics, Inc | 0.87% |
| XMTRXometry, Inc. | 0.84% |
| Total | 14.25% |
Recently Viewed
No data currently available





